Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.
about
Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tabletsAntimicrobial stewardship in paediatricsCharacteristics and programme-defined treatment outcomes among childhood tuberculosis (TB) patients under the national TB programme in DelhiPharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaInsights into the pharmacokinetic properties of antitubercular drugs.Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.Population pharmacokinetics of ethambutol in South African tuberculosis patients.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.Pharmacokinetics of ethionamide in children.Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutolChallenges of Childhood TB/HIV Management in Malawi.Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.Diagnostic and management challenges for childhood tuberculosis in the era of HIV.Advances in Drug Discovery and Development for Pediatric Tuberculosis.Treatment of tuberculosis in children.Management of community-acquired pneumonia in HIV-infected children.Pathophysiological changes that affect drug disposition in protein-energy malnourished children.Pediatric TB: issues related to current and future treatment options.Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV CoinfectionPharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.Pharmacokinetics of anti-tuberculosis drugs in children.Diagnosis and management of TB in children: an update.Protein-energy malnutrition: a risk factor for various ailments.A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children.Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children.The challenges of pharmacokinetic variability of first-line anti-TB drugs.Treatment outcome in children with tuberculosis in southern Ethiopia.Integration of childhood TB into guidelines for the management of acute malnutrition in high burden countries.Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.Challenges in childhood tuberculosis.Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.
P2860
Q21131992-D3E3990A-3CA9-4B95-A988-E87C57AE3E2EQ26740379-95ECE8AF-4830-4CC0-A785-FF96F7F3846FQ28475742-9EB15C45-9368-47DD-A528-5080DD423D85Q28550488-BCF611EF-8BCF-48CA-8BE0-B8EA4EFF3413Q30251497-D275B0F9-6DF0-48E5-B905-983A31163956Q30498213-E5578961-37CA-4D15-8B5D-DFD47D173EADQ35105834-0428FDEE-31AB-4C15-BB05-62565D7B2A5EQ35191463-8D26597E-E09E-4DC9-B70B-50B8545714C7Q35197257-3BBC922A-7840-4EE1-AD5A-743E7C8E87A4Q35215680-ECCF1B98-D5DC-4EDB-AB28-9C902D13BED8Q35270526-708679C4-8E47-48DC-A2B6-4BF794853FD6Q35598492-0BC1F3A4-E037-430B-9800-A9E31909D31CQ35837836-583F6C7F-A500-41CF-A0C6-688ABF95A01FQ35939235-D32E79DA-C584-4ECF-B4DB-F035E44A99C7Q35978007-1D304E75-C406-4CA6-B976-9CEC3BFEA4F0Q36075800-E1D17FF8-70FA-45F2-946A-CCC763A69668Q36706812-A02CD83B-9770-4B95-99A0-8099F8050F16Q36730120-A1F7D3E2-95C4-4EE2-8E06-EBF0D5F4391BQ36877242-170426F8-F3B9-44F1-8CBB-A08BF4FA1A3CQ37134041-17EEB5D4-ACBA-4C4C-97BD-93B9A2F96D35Q37340569-2079E3D0-0B9D-4F53-B090-5FD8A7701341Q37463218-F7387237-74F0-4CD8-8C8E-3B3EBE0D5AFEQ37479752-3FBC3265-8284-4DF6-929D-AD89CB3955E9Q37573756-29F0A904-2DD5-426D-849C-8F2F79F097E0Q37613004-E74F2698-51FA-4559-8C58-F3B91D8CB8C8Q37712966-D6B16F61-F718-4C05-862B-7EB1583760F1Q37821811-E5D96399-E229-4CCA-9139-28E159E3AAC7Q37960565-4BBF4B89-3C52-4D9D-9DF4-27F932140160Q38219167-E62DB368-B342-44A3-9ED3-5C8F1B35E408Q38547708-B5A9D0C9-B0B0-46FA-A35F-63AB32A6CAF9Q38673843-20E4CC6F-DA27-4421-869D-35425A67E0A0Q38977166-12073859-B386-49ED-9A7E-D06A7539D9A3Q39285450-14563A48-89F8-40E5-8C40-24E8F7D28F2AQ40140487-65FCA0E1-4D31-406C-AA7C-97F364492A39Q40282057-83B5D7E2-346D-4F82-93A8-94D94DEA4518Q40500659-2CD920D2-0BD8-42EE-9C45-3361F81288F9Q47778426-37986F10-185D-4582-BE91-23DDBE2B1A0AQ50581921-639FE463-A487-4859-A9C1-113F0F132862Q53691502-BB34AD49-7098-43C2-B2ED-57C9A50644BD
P2860
Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@ast
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@en
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@nl
type
label
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@ast
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@en
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@nl
prefLabel
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@ast
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@en
Low levels of pyrazinamide and ...... unodeficiency virus infection.
@nl
P2093
P2860
P50
P1476
Low levels of pyrazinamide and ...... munodeficiency virus infection
@en
P2093
E M Molyneux
S Nyirongo
P2860
P304
P356
10.1128/AAC.50.2.407-413.2006
P407
P577
2006-02-01T00:00:00Z